Alerta

基于SERPINA5的PASC相关心血管系统症状风险评估应用

Resumen de: CN122564109A

0001 本发明涉及生物医药技术领域，尤其是涉及基于SERPINA5的PASC相关心血管系统症状风险评估应用。本发明提供了一种以SERPINA5为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。

抗磷酸化Tau217的单克隆抗体及其试剂盒

Resumen de: CN122562946A

0001 本申请涉及一种特异性识别磷酸化 Tau217 蛋白的单克隆抗体、其制备方法，以及包含该抗体的磷酸化 Tau217 蛋白检测试剂盒，该抗体可用于阿尔茨海默病的早期辅助诊断、病程监测及疗效评估。本发明试剂盒空白限为 0.51 pg/mL，检出限为 1.04 pg/mL，定量限为 3.93 pg/mL，线性范围 0.5‑100 pg/mL（线性相关系数 r≥0.99），批内精密度 CV≤8%，批间精密度 CV≤15%，抗干扰性良好，试剂盒稳定性为 12 个月，开瓶后机载稳定期 30 天，与进口参比试剂盒相关性良好。

Polyphenol-Containing Compositions for Upregulating Camp Gene Expression

Resumen de: US20260232624A1

0000 A method is for modulating tight junction (TJ) integrity in a subject. The method includes (a) assessing TJ integrity in the subject by quantifying at least one biomarker of TJ integrity in the subject; (b) administering to the subject a first composition containing (i) at least one polyphenol, and (ii) a second substance which is not a polyphenol and which upregulates CAMP gene expression in the subject; (c) reassessing TJ integrity in the subject by quantifying at least one biomarker of TJ integrity in the subject; and (d) repeating steps (b) and (c) until the value of said at least one biomarker is within a target range.

生体膜小胞の網羅的解析方法

Resumen de: JP2026130617A

0001 【課題】 本発明は、生体膜小胞についての従来の解析方法では十分に解析できなかった生体膜小胞の機能を詳細に解析することを目的に、生体膜小胞を網羅的に解析することを課題とする。 【解決手段】 本発明は、生体膜小胞についての解析を行う際、分離または精製を行っていない生体膜小胞を解析対象とすることにより、従来法においては解析データを取得できていなかった生体膜小胞を含めすべての生体膜小胞についてのデータを取得し、そのデータを利用して生体膜小胞の網羅的解析を可能にすることを明らかにし、前記課題を解決した。 【選択図】 なし

ロイシンリッチリピートキナーゼ２（ＬＲＲＫ２）ｉＲＮＡ剤組成物およびその使用方法

Resumen de: TW202142690A

The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a leucine-rich repeat kinase 2 (LRRK2) gene, as well as methods of inhibiting expression of a LRRK2 gene and methods of treating subjects having a LRRK2-associated disease or disorder, e.g., Parkinson's disease, using such dsRNAi agents and compositions.

HUMAN PLURIPOTENT STEM CELL LINE GENETICALLY ENGINEERED TO CO-EXPRESS TUBB3 GENE AND FLUORESCENT REPORTER GENE

Resumen de: US20260234551A1

0000 Provided is a genetically engineered human pluripotent stem cell line in which an insertion sequence including a nucleotide sequence of a fluorescent reporter gene is inserted following a stop codon of the TUBB3 gene, whereby the TUBB3 gene and the fluorescent reporter gene are co-expressed. Genetic manipulation is made to express the fluorescent reporter gene in response to the expression of the TUBB3 gene, a neural cell marker, so that when the cell line is differentiated into neural cells, the fluorescent signal is observed, thereby allowing for monitoring the differentiation process.

BRAIN-DERIVED NEUROTROPHIC FACTOR-NANO LUCIFERASE TRANSGENIC RODENTS AND METHODS OF USE THEREOF

Resumen de: US20260231914A1

Described are transgenic rodents that express a brain-derived neurotrophic factor-nano luciferase fusion protein (BD-NF-NLuc) and methods of making the BDNF-NLuc rodents. Also described are methods involving these rodents and/or cell populations derived from these rodents to screen BDNF-modulating molecules.

U-p53 PEPTIDES AS MARKERS IN THE RATE OF PROGRESSION OF COGNITIVE DECLINE TO ALZHEIMER'S DISEASE

Resumen de: US20260235628A1

0000 U-p53 peptide P1 is useful in the determination of the rate of progression of Alzheimer's disease (AD). By quantitating the level of U-p53 peptides in a subject's biological sample, the rate of progression of Alzheimer's disease at the pre-clinical and prodromal stages of the disease in a subject can be determined.

LTBP COMPLEX-SPECIFIC INHIBITORS OF TGF-BETA 1 AND USES THEREOF

Resumen de: US20260234272A1

Disclosed herein are inhibitors, such as antibodies, and antigen binding portions thereof, that selectively bind complexes of LTBP1-TGFβ1 and/or LTBP3-TGFβ1. The application also provides methods of use of these inhibitors for, for example, inhibiting TGFβ1 activation, and treating subjects suffering from TGFβ1-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGFβ1 inhibitor for a subject in need thereof are also provided.

CD59 FOR INHIBITING INFLAMMASOME ACTIVATION

Resumen de: US20260232845A1

Methods and kits are provided for inhibiting inflammasome activation in cells of a subject or an inflammation-affected eye in a subject by administering to the subject a composition including a nucleotide sequence encoding a membrane independent CD59 protein operably linked to a promoter for expression and secretion of the membrane independent CD59 protein in the cells or the inflammation-affected eye, the composition inhibiting inflammasome activation.

BIOMOLECULES IN DISEASE

Resumen de: US20260235627A1

The invention relates to methods of screening for the presence of proteopathies, to methods of diagnosing proteopathies, to methods of differentially diagnosing proteopathies, to methods of assessing the severity, stage and/or prognosis of proteopathies, and to methods for monitoring the progression of proteopathies. The invention also relates to methods for determining the efficacy of therapeutic interventions for proteopathies.

ANTI-VISTA ANTIBODIES AND FRAGMENTS

Resumen de: US20260234264A1

The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.

BIOMARKERS FOR HUNTINGTON DISEASE STRATIFICATION, METHODS AND USES THEREOF

Resumen de: US20260235626A1

The present invention relates to biomarker-based analyses for the stratification of Huntington Disease (HD) in a subject. The invention further relates to protein biomarkers (and particular combinations) and their use in monitoring biochemical changes in HD patients indicative of the stage, severity, progression, or age-of-onset of disease; guidance for the design of clinical trials; for selecting a therapeutic regimen and monitoring response to treatment. The invention further comprises methods for the detection of HD biomarkers in cerebrospinal fluid (CSF) and other biofluids in patients with HD or at risk of developing HD.

BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION

Resumen de: US20260232812A1

0000 The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.

PROTEINS AND PROTEIN LIBRARIES

Resumen de: US20260234206A1

0000 The present invention relates to proteins and protein libraries particularly for use in methods of screening to identify novel binding partners including diagnostic and therapeutic molecules.

COMPOSITIONS, KITS, AND METHODS FOR DETECTING PRECLINICAL ALZHEIMER'S DISEASE

Resumen de: US20260235612A1

0000 Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD163, CD91, CD59, MerTK and other phagocytosis-related molecules. Further compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.

ENDOTHELIAL AND BLOOD-BRAIN BARRIER MARKERS OF NEUROLOGICAL DISORDERS

Resumen de: US20260235629A1

0000 Disclosed are methods, compositions, and computer-implemented systems for diagnosing, staging, and monitoring neurological and neurovascular disorders, including Alzheimer's disease, vascular dementia, traumatic brain and spinal-cord injury, stroke, demyelinating disease, and central nervous system vasculitis. The invention involves measuring levels of endothelial and blood-brain-barrier-associated biomarkers—comprising claudins 1-34 (including claudin-14 and claudin-23), endothelins (ET-1 to ET-3), ESAM, ESM1 (Endocan), neuropilins (NRP1 and NRP2), ZIC1, FOXP2, and neuroligins (NLGN 1-4 and subtypes)—in biological samples such as cerebrospinal fluid, plasma, serum, or other biofluids. Altered biomarker patterns indicate endothelial activation, barrier dysfunction, or neurovascular signaling imbalance associated with disease progression or therapeutic response. Also provided are analytical kits containing capture reagents, calibration standards, and a non-transitory computer-readable medium configured to integrate biomarker data, as well as machine-learning models trained to generate diagnostic, prognostic, or vascular-safety indices supporting individualized management of neurodegenerative and neurovascular conditions.

HUMAN NEURONAL CIRCUITS

Resumen de: WO2026166999A1

The present invention relates to a human cortico-striato-nigral circuit on chip comprising: i) a population of human striatal medium spiny neurons (MSNs) MSNs expressing MEIS2, BCL11B and GABAergic lineage markers GAD2 and DLX6-AS1, said MSNs thereby forming a medium spiny neuronal circuit, wherein said medium spiny neuronal circuit comprises at least two subpopulations of MSNs expressing dopaminergic D1- or D2- receptors; ii) a population of nigral dopaminergic neurons expressing FOXA1, LMX1A, EN1 and NR4A2, thereby forming a nigral dopaminergic neuronal circuit; and iii) a population of cortical glutamatergic neurons expressing LHX2 and SLC17A6 and/or SLC17A7, thereby forming cortical circuit; a multi-electrode array (MEA) chip for recording neuronal activity, said neuronal activity resulting at least in part from dopaminergic, GABAergic and/or glutamatergic neurotransmission; wherein said medium spiny neuronal circuit is spatially arranged onto said MEA chip for receiving excitatory and/or modulatory inputs from said cortical circuit iii) and/or said nigral dopaminergic circuit ii); and wherein each one of said populations i)-iii) are differentiated from a human pluripotent stem cell. The present invention further relates to a method for producing said cortico-striato-nigral circuit on chip, and a method of determining the effect of a candidate agent on neuronal activity of the cortico-striato- nigral circuits on chip.

T CELL RECEPTORS AND MODIFIED T CELLS FOR NEURODEGENERATIVE AND OTHER INFLAMMATORY DISORDERS

Resumen de: WO2026170050A1

In one aspect, the present invention provides nucleic acids encoding T cell receptor alpha and beta chains which can associate with each other in order to form functional T cell receptors (TCRs) specific for cryptic epitopes of, for example, HDGFL2 protein, IgLON5 protein and others expressed by a target cell. In other aspects, the invention provides T cell receptors (TCRs) specific for cryptic epitopes, modified T cells expressing the T cell receptors, methods for generating the modified T cells, and diagnostic/screening methods for identifying subjects expressing TCRs comprising antigen specificities for cryptic peptides associated with TDP-43 proteinopathies. In further aspects, the invention provides a method for stimulating an immune response, treating a subject with a TDP-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS) or inclusion body myositis (IBM), and detecting a TDP-43 proteinopathy-associated immune signature in a subject.

PATHOLOGIC TDP-43 AS A BIOMARKER FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHY

Resumen de: US20260234229A1

Disclosed herein are antibodies or antigen-binding fragments thereof and compositions comprising the same. Also disclosed are methods of detecting TAR DNA-binding protein 43 (TDP-43) in a biological sample, diagnosing a neurodegenerative disease in a subject, and selecting whether to enroll a subject in a clinical trial for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) using the antibodies or antigen-binding fragments thereof described herein. In addition, disclosed herein are immunoassay kits for selectively detecting TDP-43 in a biological sample.

METHODS FOR DETERMINING ABNORMAL CSF FLOW

Resumen de: WO2026167161A1

The present invention relates to biomarkers of cerebrospinal fluid (CSF) flow, methods for determining the synthesis rate and clearance rate of biomolecules in CSF of a subject, methods for determining abnormal CSF flow in a subject and diagnosing and treating disorders associated with abnormal CSF flow.

GDF11 BIOMARKERS, METHODS, AND COMPOSITIONS FOR TREATING STROKE

Resumen de: WO2026169642A2

The disclosure relates to methods of treating stroke, dosing regimens of GDF11, and post-stroke treatment with GDF11.

METHOD OF DIAGNOSING A SUBPOPULATION OF SUBJECTS WITH A POST-COVID-19 CONDITION AND OF TREATING THE SUBJECTS USING BAFF INHIBITION

Resumen de: WO2026165666A1

The present disclosure provides a method for treating long CO VID ( e.g., severe long CO VID) or at least one symptom thereof in a subpopulation of subjects displaying a combination of biomarkers namely a blood level of secreted B-cell activating factor and of membrane BAFF in white blood cells higher than a corresponding reference level; and at least one of blood level of precursor- like marginal zone B-cell populations, zonulin, anti-Mi-2 nuclear antigen autoantibodies, anti-SmD autoantibodies, anti-Ul-snRNP-A autoantibodies, anti-RCN2 autoantibodies, lipopolysaccharide-binding protein (LBP), and p-D-glucan higher than a corresponding reference level, and APRIL lower than a corresponding reference level, comprising administering a therapeutically effective amount of a BAFF inhibitor to the subject. It also provides a method of diagnosing a subject as having long CO VID using the combination of biomarkers and a diagnosis kit comprising ligands for the biomarkers.

METHODS AND COMPOSITIONS FOR TREATING HEART FAILURE WITH REDUCED EJECTION FRACTION

Resumen de: WO2026169645A1

Embodiments provided herein relate to methods, compositions and uses for treating heart failure with reduced ejection fraction (HFrEF). Some embodiments relate to methods, compositions and uses of a recombinant viral vector encoding a 2a isoform of a sarco(endo)plasmic reticulum calcium ion (Ca2+) ATPase (SERCA2a) protein.

METHOD OF IMAGING BIOMOLECULES

Nº publicación: US20260235515A1 13/08/2026

Solicitante:

RAMOT AT TEL AVIV UNIV LTD [IL]
Ramot at Tel-Aviv University Ltd.

Resumen de: US20260235515A1

Identification of molecular species in a sample based unique fluorescent labeling, light dispersion, and image processing. The molecular species identification methods can be used for diagnosing diseases.